10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.

BACKGROUND In the 2.8 years of the Diabetes Prevention Program (DPP) randomised clinical trial, diabetes incidence in high-risk adults was reduced by 58% with intensive lifestyle intervention and by 31% with metformin, compared with placebo. We investigated the persistence of these effects in the long term. METHODS All active DPP participants were eligible for continued follow-up. 2766 of 3150 (88%) enrolled for a median additional follow-up of 5.7 years (IQR 5.5-5.8). 910 participants were from the lifestyle, 924 from the metformin, and 932 were from the original placebo groups. On the basis of the benefits from the intensive lifestyle intervention in the DPP, all three groups were offered group-implemented lifestyle intervention. Metformin treatment was continued in the original metformin group (850 mg twice daily as tolerated), with participants unmasked to assignment, and the original lifestyle intervention group was offered additional lifestyle support. The primary outcome was development of diabetes according to American Diabetes Association criteria. Analysis was by intention-to-treat. This study is registered with ClinicalTrials.gov, number NCT00038727. FINDINGS During the 10.0-year (IQR 9.0-10.5) follow-up since randomisation to DPP, the original lifestyle group lost, then partly regained weight. The modest weight loss with metformin was maintained. Diabetes incidence rates during the DPP were 4.8 cases per 100 person-years (95% CI 4.1-5.7) in the intensive lifestyle intervention group, 7.8 (6.8-8.8) in the metformin group, and 11.0 (9.8-12.3) in the placebo group. Diabetes incidence rates in this follow-up study were similar between treatment groups: 5.9 per 100 person-years (5.1-6.8) for lifestyle, 4.9 (4.2-5.7) for metformin, and 5.6 (4.8-6.5) for placebo. Diabetes incidence in the 10 years since DPP randomisation was reduced by 34% (24-42) in the lifestyle group and 18% (7-28) in the metformin group compared with placebo. INTERPRETATION During follow-up after DPP, incidences in the former placebo and metformin groups fell to equal those in the former lifestyle group, but the cumulative incidence of diabetes remained lowest in the lifestyle group. Prevention or delay of diabetes with lifestyle intervention or metformin can persist for at least 10 years. FUNDING National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

[1]  G. Bray,et al.  The prevention of type 2 diabetes , 2008, Nature Clinical Practice Endocrinology &Metabolism.

[2]  G. Bray,et al.  First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes , 2008, International Journal of Obesity.

[3]  Bo Zhang,et al.  The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study , 2008, The Lancet.

[4]  K. Narayan,et al.  Prevention of type 2 diabetes , 2001, BMJ : British Medical Journal.

[5]  Colin Mathers,et al.  The burden of mortality attributable to diabetes: realistic estimates for the year 2000. , 2005, Diabetes care.

[6]  M. Molitch.  Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. , 2003, Diabetes care.

[7]  J. Lindström,et al.  Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study , 2006, The Lancet.

[8]  B. Howard,et al.  Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance: The Da Qing IGT and Diabetes Study , 1997, Diabetes Care.

[9]  M. Laakso,et al.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.

[10]  Claude Bouchard,et al.  Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. , 2004, The New England journal of medicine.

[11]  E. Barrett-Connor,et al.  Strategies to identify adults at high risk for type 2 diabetes: the Diabetes Prevention Program. , 2005, Diabetes care.

[12]  Helen Brown,et al.  Applied Mixed Models in Medicine , 2000, Technometrics.

[13]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[14]  M. Laakso,et al.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.

[15]  Melvin Prince,et al.  The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. , 1999, Diabetes care.

[16]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[17]  Nicola J Cooper,et al.  Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis , 2007, BMJ : British Medical Journal.

[18]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[19]  S. Fowler,et al.  Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. , 2005, Diabetes care.

[20]  P. Diggle.  Analysis of Longitudinal Data , 1995 .

[21]  P. Bennett,et al.  The natural history of impaired glucose tolerance in the Pima Indians. , 1988, The New England journal of medicine.

[22]  Stephen W. Sorensen,et al.  The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance , 2005, Annals of Internal Medicine.

[23]  M. Engelgau.  Trying To Predict the Future for People with Diabetes: A Tough but Important Task , 2005, Annals of Internal Medicine.

[24]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[25]  J. Shaw,et al.  Follow-up report on the diagnosis of diabetes mellitus. , 2003, Diabetes care.

[26]  C. Snehalatha,et al.  The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1) , 2006, Diabetologia.

[27]  R. Kahn,et al.  Managing People at High Risk for Diabetes , 2006 .

[28]  S. Fowler,et al.  Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. , 2005, Diabetes.